Some of these include prominent glycoprotein biomarkers that are widely monitored in patients with prostate cancer (prostate-specific antigen (PSA)), ovarian cancer (carcinoma antigen (CA)125, mucin 16), colon cancer (carcinoembryonic antigen (CEA)), and non-seminomatous testicular carcinoma (human chorionic gonadotropin β-subunit (hCG-β)) (Table 1). This evidence concerns the gene CEACAM5 and prostate carcinoma.